Xilio Therapeutics Q3 2026 Earnings Date & Estimates

Xilio Therapeutics (NASDAQ:XLO) is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments. Its pipeline is intended to stimulate immune responses within solid tumors and potentially address cancers that have limited responses to existing immunotherapies. The company’s programs remain in clinical development and are subject to the risks and uncertainties associated with biotechnology research.

Founded in 2020 and headquartered in Waltham, Massachusetts, Xilio Therapeutics serves the global oncology market through its drug-discovery and clinical-development activities. The company became publicly traded on the Nasdaq under the symbol XLO in 2021. Xilio is led by René Russo, who serves as president and chief executive officer.